• 四川大學(xué)華西醫(yī)院胃腸外科中心（四川成都 610041）;

引用本文： 胡建昆,陳心足. 胃癌多學(xué)科協(xié)作診療模式現(xiàn)狀. 中國(guó)普外基礎(chǔ)與臨床雜志, 2012, 19(1): 1-3. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology： gastric cancer. V.1.2011 NCCN, 2011. http：//www.nccn.org.
2. 黃子星,陳心足,宋彬,等 . 64排螺旋 CT對(duì)Ⅳ期胃癌術(shù)前分期的價(jià)值[ J].中國(guó)普外基礎(chǔ)與臨床雜志 , 2008, 15(8)：623-627.[3] Chen XZ, Yang K, Zhang B, et al. Is retrieval of ＞ 25 lymph nodes a superior criterion for locally advanced gastric cancer sur-gery?[J]. Ann Surg, 2011, 254(5)：834-835.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesopha-geal junction cancer (ToGA)：a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742)：687-697.
4. Chen XZ, Hu JK, Yang K, et al. Short-term evaluation of lapa-roscopy-assisted distal gastrectomy for predictive early gastric cancer：a meta-analysis of randomized controlled trials[J]. Surg Laparosc Endosc Percutan Tech, 2009, 19：277-284.
5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3)[J]. Gastric Cancer, 2011, 14(2)：113-123.
6. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer： 15-year follow-up results of the randomised na-tionwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5)：439-449.
7. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer：a meta-analysis[J]. JAMA, 2010, 303(17)：1729-1737.
8. Hu JK, Li CM, Chen XZ, et al. The effectiveness of intravenous 5-fluorouracil-containing chemotherapyafter curative resectionfor gastric carcinoma：A systematic review of published randomized controlled trials[J]. J Chemother, 2007, 19(4)：359-375.
9. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemo-therapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18)：1810-1820.
10. Li W, Qin J, Sun YH, et al. Neoadjuvant chemotherapy for ad-vanced gastric cancer： a meta-analysis[J]. World J Gastroen-terol, 2010, 16(44)：5621-5628.
11. Chen XZ, Yang K, et al. Neoadjuvant plus adjuvant chemo-therapy benefits overall survival of locally advanced gastric can-cer[J]. World J Gastroenterol, 2011, 17(40)：4542-4544.
12. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1)：11-20.
  1. 1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology： gastric cancer. V.1.2011 NCCN, 2011. http：//www.nccn.org.
  2. 2. 黃子星,陳心足,宋彬,等 . 64排螺旋 CT對(duì)Ⅳ期胃癌術(shù)前分期的價(jià)值[ J].中國(guó)普外基礎(chǔ)與臨床雜志 , 2008, 15(8)：623-627.[3] Chen XZ, Yang K, Zhang B, et al. Is retrieval of ＞ 25 lymph nodes a superior criterion for locally advanced gastric cancer sur-gery?[J]. Ann Surg, 2011, 254(5)：834-835.
  3. 3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesopha-geal junction cancer (ToGA)：a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742)：687-697.
  4. 4. Chen XZ, Hu JK, Yang K, et al. Short-term evaluation of lapa-roscopy-assisted distal gastrectomy for predictive early gastric cancer：a meta-analysis of randomized controlled trials[J]. Surg Laparosc Endosc Percutan Tech, 2009, 19：277-284.
  5. 5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3)[J]. Gastric Cancer, 2011, 14(2)：113-123.
  6. 6. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer： 15-year follow-up results of the randomised na-tionwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5)：439-449.
  7. 7. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer：a meta-analysis[J]. JAMA, 2010, 303(17)：1729-1737.
  8. 8. Hu JK, Li CM, Chen XZ, et al. The effectiveness of intravenous 5-fluorouracil-containing chemotherapyafter curative resectionfor gastric carcinoma：A systematic review of published randomized controlled trials[J]. J Chemother, 2007, 19(4)：359-375.
  9. 9. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemo-therapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18)：1810-1820.
  10. 10. Li W, Qin J, Sun YH, et al. Neoadjuvant chemotherapy for ad-vanced gastric cancer： a meta-analysis[J]. World J Gastroen-terol, 2010, 16(44)：5621-5628.
  11. 11. Chen XZ, Yang K, et al. Neoadjuvant plus adjuvant chemo-therapy benefits overall survival of locally advanced gastric can-cer[J]. World J Gastroenterol, 2011, 17(40)：4542-4544.
  12. 12. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1)：11-20.